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LETTERS
Falciparum Malaria 
in Patient 9 Years 
after Leaving 
Malaria-Endemic 
Area 
To the Editor: A 30-year-old Afri-
can man, without any speciﬁ  c medical 
history, came to the emergency depart-
ment of Brugmann University Hospi-
tal in Brussels, Belgium, on March 
18, 2008, because of malaise, profuse 
transpiration, and dizziness that day. 
He also reported a 3-day history of 
muscle pain and pain while urinating, 
for which his general practitioner pre-
scribed ciproﬂ  oxacin. Originally from 
Guinea-Conakry, the patient reported 
no travel outside Belgium after his 
arrival >9 years earlier. No recurrent 
fever episodes were noted during this 
period. Two weeks before becoming 
ill, a friend visiting from Guinea-Con-
akry stayed at his home for 7 days.
Results of a physical examination 
were normal, except for a temperature 
of 37.5°C. Blood analysis showed 
moderate anemia (hemoglobin 12.9 
g/dL) and thrombocytopenia (platelet 
count 73,000/μL) with total bilirubin 
and C-reactive protein levels of 1.5 mg/
dL and 7.0 mg/dL, respectively. Be-
cause we suspected subfebrile malaria 
in this patient, a blood smear was pre-
pared. It showed ring-shaped tropho-
zoites of Plasmodium falciparum with 
a parasite density of 0.1%. Serologic 
tests showed an antibody titer to Plas-
modium spp. of 3,200. A blood sam-
ple was sent to the national reference 
laboratory at the Institute of Tropical 
Medicine in Antwerp. The diagnosis of 
P. falciparum malaria was conﬁ  rmed 
by microscopy and real-time PCR. 
Follow-up was uneventful because the 
patient responded to a 7-day course of 
oral quinine and doxycycline.
Malaria, a potential life-threaten-
ing disease caused by P. falciparum, 
usually occurs within 2 months after 
the bite of an infective mosquito. A 
few reports mention a delay of >1 year 
between exposure and initial clini-
cal symptoms, probably related to the 
disappearance of residual protective 
immunity in immigrants (1,2). Im-
paired immunity has also been linked 
to late malaria, implicating a chronic 
low-grade  P.  falciparum infection 
that becomes clinically evident in 
an immunocompromised person (3). 
In addition, several cases of malaria 
without any travel history to a malaria-
endemic region have been described. 
A possible explanation for this type 
of malaria is exposure to an imported 
Anopheles spp. mosquito, referred to 
as airport, luggage, or container ma-
laria (4). Transmission by indigenous 
anopheline mosquitoes when weather 
conditions are favorable has been re-
ported in some European countries 
(5,6). Cases of P. falciparum malaria 
without any evidence of a mosquito 
bite have been reported and related 
to transfusion of parasitized erythro-
cytes, intravenous drug use, or acci-
dental needlestick injuries (4).
We report a clinically atypical 
case of late P. falciparum malaria that 
may have been contracted by the bite 
of an anopheline mosquito captured 
in the luggage of the patient’s visiting 
friend (7). Unreported travel to a ma-
laria-endemic region was possible but 
unlikely because our patient stayed 
illegally in Belgium and leaving the 
country would risk being repatriated 
to Guinea-Conakry. Indigenous ma-
laria was excluded because he became 
ill during the winter, a time when pro-
liferation of local Anopheles spp. in 
Belgium is difﬁ  cult. The patient did 
not receive any recent blood transfu-
sions and denied being an intravenous 
drug user, although this possibility 
cannot be excluded.
This type of malaria, also known 
as luggage or suitcase malaria, makes 
adequate and timely diagnosis difﬁ  -
cult because a history of exposure to 
a possibly malaria-infected mosquito 
is apparently absent. Moreover, our 
patient had few classic symptoms or 
signs, such as high-grade fever, chills, 
or headaches; this pattern complicates 
diagnosis. This lack of typical malaria 
symptoms may be related to the fact 
that before coming to the hospital, the 
patient took ciproﬂ  oxacin, which has 
in vitro activity against P. falciparum. 
Another possible reason is residual 
immunity to malaria, which was no 
longer protective but still capable of 
attenuating symptoms or signs of ma-
laria. This ﬁ  nding implicates recrudes-
cence of disease after a long period of 
asymptomatic infection with P.  fal-
ciparum. Serologic analysis detected 
high levels of antibodies to Plasmo-
dium spp., which suggests a chronic 
infection rather than a new one.
It is generally accepted that pro-
tective immunity wanes after several 
months of nonexposure. Support for 
this thesis is the frequency of clini-
cal malaria in African adults who 
visit their families after a long stay 
in a country where the disease is not 
endemic. However, these cases might 
be caused by antigenic variation of P. 
falciparum in the area visited, which 
would enable the parasite to evade the 
host’s immune response (8). Residual 
immunologic memory against P. fal-
ciparum has been suggested, which 
would link persistent immunity with 
late recrudescence or with less severe 
or complicated disease in immigrants 
(2,9). Moreover, P.  falciparum has 
been transmitted through blood trans-
fusions from donors from malaria-en-
demic regions several years after ex-
posure, which suggests long subpatent 
periods (10).
This case highlights the problem 
of diagnosing P.  falciparum malaria 
in patients without a recent travel his-
tory to malaria-endemic areas. In such 
cases, autochthonous malaria, whether 
transmitted by an imported or an indig-
enous mosquito or by infected blood 
cells or needles, should be excluded. 
Residual protective immunity, even 
after several years of nonexposure to 
P. falciparum, may explain persistent 
asymptomatic infection and late recru-
descence of disease.
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Linezolid-Resistant 
Staphylococcus 
cohnii, Greece
To the Editor: Since 2003, li-
nezolid has typically been used to 
treat infections caused by multidrug-
resistant gram-positive cocci such 
as vancomycin-resistant Enterococ-
cus faecium and methicillin-resistant 
Staphylococcus aureus (1). In Greece, 
a major problem is nosocomial dis-
semination of vancomycin-resistant 
enterococci. Use of linezolid for the 
treatment of such infections led to the 
emergence of linezolid–vancomycin 
resistant E. faecium; however, linezol-
id resistance of staphylococci is still 
relatively low in this country (2). We 
describe an outbreak caused by a line-
zolid-resistant S. cohnii in an intensive 
care unit (ICU) in Greece.
From July through October 2007, 
nonrepetitive coagulase-negative sta-
phylococci that exhibited resistance 
to linezolid, were isolated from blood 
cultures from 4 separate patients hos-
pitalized in the ICU at Sismanoglion 
General Hospital of Athens, a 450-bed 
tertiary care hospital. The ICU is a 10-
bed, level II unit, comprising 2 rooms 
with 1 bed each and 2 rooms with 4 
beds each. Each isolate was recovered 
in 2 of 2 blood culture sets per patient, 
indicating true bacteremia. The demo-
graphic and clinical information for 
the patients is described in the Table. 
The mean duration of time preceding 
linezolid therapy was 22 days.
Isolates were ﬁ  rst  identiﬁ  ed  to 
the species level by using an API 
Staph system (bioMérieux, la Balme 
les Grottes, France) and a molecular 
method based on the tuf gene followed 
by sequencing analysis (3). Suscepti-
bility testing for various antimicrobial 
agents was performed by disk diffu-
sion and using Clinical Laboratory 
Standards Institute criteria; suscep-
tibilities were interpreted according 
to Institute guidelines (4). In addi-
tion, MICs to oxacillin, vancomycin, 
teicoplanin, quinupristin-dalfopristin, 
linezolid, daptomycin, and tigecy-
cline were determined by Etest (AB 
Biodisk, Solna, Sweden) according 
to manufacturer’s instructions. Re-
sistance genes mecA, vat,  vga, erm, 
aac(6´)-Ie+aph(2″),  ant(4′)-Ia, and 
aph(3′)-IIIa, as markers for resistance 
to β-lactams, dalfopristin, macrolides, 
and aminoglycosides, were identiﬁ  ed 
by PCR as previously reported (5,6). 
The presence of G2576T in domain 
V of the 23S rRNA, which is mainly 
associated with linezolid resistance in 
clinical isolates, was detected by us-
ing PCR and digestion of the product 
with NheI (2). The number of mutated 
versus nonmutated alleles was deter-
mined as described by Pillai et al. (7). 
In addition, isolates were examined 
for the presence of the cfr gene, which 
was found to be correlated with lin-
ezolid resistance in some coagulase-
negative staphylococci and for mu-
tations of ribosomal protein L4, L22 
genes (8,9). Clonality of isolates was 
assessed by pulsed-ﬁ  eld gel electro-
phoresis (PFGE) after digestion of 
chromosomal DNA with SmaI (2).
The molecular method identiﬁ  ed 
the isolates as S. cohnii subsp. ure-
olyticus. The API Staph system has 
correctly identiﬁ  ed 2 of them; the re-
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